The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%.
Tootsie Roll Industries, Inc.
TR · the NYSE · USD · Market cap $2.9B · 2,100 employees
Tootsie Roll Industries, Inc., together with its subsidiaries, manufactures and sells confectionery products in the United States, Canada, Mexico, and internationally.
PASS · Titan Ethical · score 70.0Price as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price38.28 USD at the 13 Nov 2026 close
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.15)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.15, read 2026-11-15
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Tootsie Roll Industries, Inc. holds its Distribution at $38.28. Consolidating, no directional conviction, held for 11 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 11 days |
| Price at the screen | $38.28 |
| Valuation | 31.05 trailing · -20.06 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.41 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 1.11% | Below 33% | Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 3.94% | Below 33% | Cash held in interest-bearing accounts and securities is 3.9% of assets, under the one-third limit. | Pass |
| Receivables | 13.96% | Below 49% | Money owed to the company is 14.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 2.76% | Below 5% | Only 2.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Tootsie Roll Industries, clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TR's ethical verdict changes
Today TR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
| Forward P/E | -20.1x |
| Trailing P/E | 31.0xa premium valuation |
| EPS, trailing | 1.26 |
| EPS, forward | -1.95 |
| Revenue growth | -0.6%revenue is shrinking |
| Profit margin | 13.0%thin but positive margins |
| Return on equity | 10.3%a modest return on shareholder capital |
| FCF yield | 2.02% |
| Dividend yield | 0.95% |
| Debt to equity | 1.40a meaningful debt load worth watching |
| Current ratio | 2.89comfortably covers its short-term bills |
| Beta | 0.41barely tracks the market's swings |
| Short interest, float | 0.08% |
| 52-week range | 33.91 - 45.06 |
| Market cap | $2.9B |
| Employees | 2,100 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeTR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 18%. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Which Gives You More Of A Profit Rebound, Mondelez Or Hershey? Yahoo Finance · 4d ago
- Tootsie Roll: Q3 Earnings Snapshot Yahoo Finance · 9d ago
- Tootsie Roll (TR) Stock May Be Overvalued As Its 48% Run Continues Yahoo Finance · 29d ago
- Can Hershey's Q2 Margin Rebound Extend as Pricing Pressures Volume? Zacks · 26 Aug 2026
- Can Hershey's Q2 Margin Rebound Extend as Pricing Pressures Volume? Yahoo Finance · 26 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-30 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-10-23 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-10-22 | Chuck Fleischmann | Republican | buy | 1K–15K |
| 2026-10-22 | Chuck Fleischmann | Republican | sell | 1K–15K |
| 2026-10-22 | Chuck Fleischmann | Republican | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $40.78 | -3.2% | · | $968 | -3.2% |
| 2 months | $44.23 | -10.7% | · | $893 | -10.7% |
| 3 months | $41.32 | -4.5% | · | $956 | -4.5% |
| 6 months | $36.78 | +7.4% | $0.17 | $1,078 | +7.8% |
| 1 year | $32.62 | +21.0% | $0.35 | $1,221 | +22.1% |
| 2 years | $26.44 | +49.3% | $0.69 | $1,519 | +51.9% |
| 3 years | $34.13 | +15.7% | $1.02 | $1,187 | +18.7% |
| 5 years | $28.42 | +38.9% | $1.65 | $1,447 | +44.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.